JP2016513069A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2016513069A5 JP2016513069A5 JP2015540830A JP2015540830A JP2016513069A5 JP 2016513069 A5 JP2016513069 A5 JP 2016513069A5 JP 2015540830 A JP2015540830 A JP 2015540830A JP 2015540830 A JP2015540830 A JP 2015540830A JP 2016513069 A5 JP2016513069 A5 JP 2016513069A5
- Authority
- JP
- Japan
- Prior art keywords
- formulation
- aqueous
- dvd
- protein
- buffer
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000013011 aqueous formulation Substances 0.000 claims 2
- 238000009472 formulation Methods 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
- 102000004169 proteins and genes Human genes 0.000 claims 1
- 108090000623 proteins and genes Proteins 0.000 claims 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261721364P | 2012-11-01 | 2012-11-01 | |
| US61/721,364 | 2012-11-01 | ||
| US201361794231P | 2013-03-15 | 2013-03-15 | |
| US61/794,231 | 2013-03-15 | ||
| PCT/US2013/068110 WO2014071212A2 (en) | 2012-11-01 | 2013-11-01 | Stable dual variable domain immunoglobulin protein formulations |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019118152A Division JP2019189633A (ja) | 2012-11-01 | 2019-06-26 | 安定な二重可変ドメイン免疫グロブリンタンパク質製剤 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2016513069A JP2016513069A (ja) | 2016-05-12 |
| JP2016513069A5 true JP2016513069A5 (enExample) | 2016-12-22 |
Family
ID=49585619
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015540830A Pending JP2016513069A (ja) | 2012-11-01 | 2013-11-01 | 安定な二重可変ドメイン免疫グロブリンタンパク質製剤 |
| JP2019118152A Pending JP2019189633A (ja) | 2012-11-01 | 2019-06-26 | 安定な二重可変ドメイン免疫グロブリンタンパク質製剤 |
| JP2020178626A Pending JP2021020943A (ja) | 2012-11-01 | 2020-10-26 | 安定な二重可変ドメイン免疫グロブリンタンパク質製剤 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019118152A Pending JP2019189633A (ja) | 2012-11-01 | 2019-06-26 | 安定な二重可変ドメイン免疫グロブリンタンパク質製剤 |
| JP2020178626A Pending JP2021020943A (ja) | 2012-11-01 | 2020-10-26 | 安定な二重可変ドメイン免疫グロブリンタンパク質製剤 |
Country Status (15)
| Country | Link |
|---|---|
| US (3) | US20140161817A1 (enExample) |
| EP (2) | EP3466973A1 (enExample) |
| JP (3) | JP2016513069A (enExample) |
| KR (1) | KR20150079866A (enExample) |
| CN (1) | CN105431453A (enExample) |
| AU (3) | AU2013337644A1 (enExample) |
| BR (1) | BR112015009924A2 (enExample) |
| CA (1) | CA2889488A1 (enExample) |
| HK (1) | HK1213204A1 (enExample) |
| IL (2) | IL238264A0 (enExample) |
| MX (2) | MX2015005495A (enExample) |
| RU (2) | RU2020139283A (enExample) |
| SG (2) | SG10201802044RA (enExample) |
| TW (3) | TW202033215A (enExample) |
| WO (1) | WO2014071212A2 (enExample) |
Families Citing this family (31)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PE20121647A1 (es) | 2009-08-29 | 2012-12-31 | Abbvie Inc | Proteinas terapeuticas de union a dll4 |
| SG10201501562VA (en) | 2010-03-02 | 2015-04-29 | Abbvie Inc | Therapeutic dll4 binding proteins |
| TW201206473A (en) | 2010-08-03 | 2012-02-16 | Abbott Lab | Dual variable domain immunoglobulins and uses thereof |
| HK1212359A1 (en) | 2012-11-01 | 2016-06-10 | Abbvie Inc. | Anti-vegf/dll4 dual variable domain immunoglobulins and uses thereof |
| US20150203592A1 (en) | 2013-12-02 | 2015-07-23 | Abbvie Inc. | Compositions and methods for treating osteoarthritis |
| US20150291689A1 (en) | 2014-03-09 | 2015-10-15 | Abbvie, Inc. | Compositions and Methods for Treating Rheumatoid Arthritis |
| ES2607489T3 (es) | 2014-05-23 | 2017-03-31 | Ares Trading S.A. | Composición farmacéutica líquida |
| EP2946766B1 (en) | 2014-05-23 | 2016-03-02 | Ares Trading S.A. | Liquid pharmaceutical composition |
| ES2600488T3 (es) * | 2014-05-23 | 2017-02-09 | Ares Trading S.A. | Composición farmacéutica líquida |
| US20160002326A1 (en) | 2014-06-10 | 2016-01-07 | Abbvie Inc. | Compositions and methods for treating rheumatoid arthritis |
| US9840553B2 (en) | 2014-06-28 | 2017-12-12 | Kodiak Sciences Inc. | Dual PDGF/VEGF antagonists |
| WO2016094881A2 (en) | 2014-12-11 | 2016-06-16 | Abbvie Inc. | Lrp-8 binding proteins |
| WO2016118921A1 (en) | 2015-01-24 | 2016-07-28 | Abbvie, Inc. | Compositions and methods for treating psoriatic arthritis |
| TW201710286A (zh) | 2015-06-15 | 2017-03-16 | 艾伯維有限公司 | 抗ｖｅｇｆ、ｐｄｇｆ及／或其受體之結合蛋白 |
| US11197934B2 (en) * | 2015-09-17 | 2021-12-14 | The Scripps Research Institute | Dual variable domain immunoconjugates and uses thereof |
| AU2016382786A1 (en) * | 2015-12-29 | 2018-07-19 | Outlook Therapeutics, Inc. | Buffered formulations of bevacizumab |
| WO2017117464A1 (en) | 2015-12-30 | 2017-07-06 | Kodiak Sciences Inc. | Antibodies and conjugates thereof |
| CN108261391B (zh) * | 2016-12-30 | 2022-03-01 | 江苏太平洋美诺克生物药业有限公司 | 稳定的包含cd147单克隆抗体的药物制剂 |
| CN108261544B (zh) * | 2016-12-30 | 2023-05-05 | 江苏太平洋美诺克生物药业股份有限公司 | 稳定的包含cd147单克隆抗体的药物制剂 |
| BR112020000566A2 (pt) * | 2017-07-28 | 2020-07-21 | F. Hoffmann-La Roche Ag | formulação farmacêutica, uso da formulação e invenção |
| BR112020017872A2 (pt) | 2018-03-02 | 2020-12-22 | Kodiak Sciences Inc. | Anticorpos de il-6 e construtos de fusão e conjugados dos mesmos |
| US20210115156A1 (en) * | 2018-04-13 | 2021-04-22 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Fc-engineered anti-human ige antibodies and methods of use |
| MX2021009851A (es) | 2019-02-18 | 2021-09-10 | Lilly Co Eli | Formulacion de anticuerpos terapeuticos. |
| CN110585430B (zh) * | 2019-09-29 | 2023-09-08 | 华博生物医药技术（上海）有限公司 | 一种人源化抗人il-17a单克隆抗体的药物组合物 |
| WO2021072265A1 (en) | 2019-10-10 | 2021-04-15 | Kodiak Sciences Inc. | Methods of treating an eye disorder |
| CN113082203B (zh) * | 2020-01-09 | 2023-10-20 | 鲁南制药集团股份有限公司 | 一种免疫抑制剂单克隆抗体的液体制剂 |
| WO2021215375A1 (ja) * | 2020-04-20 | 2021-10-28 | 塩野義製薬株式会社 | Ｈｍｇｂ１部分ペプチドを含有する製剤 |
| JP2023548346A (ja) * | 2020-11-11 | 2023-11-16 | ハン，ハック | アクチビン／ｔｇｆ－ベータおよびｒａｎｋｌの二機能性アンタゴニストならびにその使用 |
| WO2022113105A1 (en) * | 2020-11-25 | 2022-06-02 | Dr. Reddy's Laboratories Limited | Stable therapeutic protein formulation and methods of making the same |
| WO2025231015A1 (en) * | 2024-04-30 | 2025-11-06 | Context Therapeutics Inc. | Compositions comprising bispecific antibodies that bind to claudin 6 and cd3, and uses thereof |
| CN120346170A (zh) * | 2025-03-13 | 2025-07-22 | 武汉友芝友生物制药股份有限公司 | 抗EpCAM和CD3双特异性抗体药物组合物 |
Family Cites Families (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CU22545A1 (es) | 1994-11-18 | 1999-03-31 | Centro Inmunologia Molecular | Obtención de un anticuerpo quimérico y humanizado contra el receptor del factor de crecimiento epidérmico para uso diagnóstico y terapéutico |
| US4753894A (en) | 1984-02-08 | 1988-06-28 | Cetus Corporation | Monoclonal anti-human breast cancer antibodies |
| US4943533A (en) | 1984-03-01 | 1990-07-24 | The Regents Of The University Of California | Hybrid cell lines that produce monoclonal antibodies to epidermal growth factor receptor |
| IL85035A0 (en) | 1987-01-08 | 1988-06-30 | Int Genetic Eng | Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same |
| JP3040121B2 (ja) | 1988-01-12 | 2000-05-08 | ジェネンテク，インコーポレイテッド | 増殖因子レセプターの機能を阻害することにより腫瘍細胞を処置する方法 |
| DK0531472T3 (da) | 1991-03-06 | 2003-12-01 | Merck Patent Gmbh | Humaniserede monoklonale antistoffer |
| US5736137A (en) | 1992-11-13 | 1998-04-07 | Idec Pharmaceuticals Corporation | Therapeutic application of chimeric and radiolabeled antibodies to human B lymphocyte restricted differentiation antigen for treatment of B cell lymphoma |
| GB9401182D0 (en) | 1994-01-21 | 1994-03-16 | Inst Of Cancer The Research | Antibodies to EGF receptor and their antitumour effect |
| AU6267896A (en) | 1995-06-07 | 1996-12-30 | Imclone Systems Incorporated | Antibody and antibody fragments for inhibiting the growth oftumors |
| DE69721548T2 (de) | 1996-02-09 | 2004-04-01 | Abbott Laboratories(Bermuda)Ltd. | HUMANE ANTIKÖRPER WELCHE AN HUMANEN TNFalpha BINDEN |
| US6235883B1 (en) | 1997-05-05 | 2001-05-22 | Abgenix, Inc. | Human monoclonal antibodies to epidermal growth factor receptor |
| US6914128B1 (en) | 1999-03-25 | 2005-07-05 | Abbott Gmbh & Co. Kg | Human antibodies that bind human IL-12 and methods for producing |
| CN1427891A (zh) | 2000-02-25 | 2003-07-02 | 美国政府由(美国)卫生和福利部部长代表 | 具有提高的细胞毒性和产量的抗EGFRvIII的scFv、基于其的免疫毒素、及其应用方法 |
| BR0110927A (pt) | 2000-05-19 | 2003-03-11 | Scancell Ltd | Anticorpo, ácido nucléico, vetor, célula, método de fabricar um anticorpo, composição farmacêutica, uso de um anticorpo ou de um ácido nucleico, e, método para o tratamento ou profilaxia do câncer |
| EP2386575A3 (en) * | 2000-06-29 | 2011-11-30 | Abbott Laboratories | Dual specificity antibodies and methods of making and using |
| US7968684B2 (en) | 2003-11-12 | 2011-06-28 | Abbott Laboratories | IL-18 binding proteins |
| US7612181B2 (en) | 2005-08-19 | 2009-11-03 | Abbott Laboratories | Dual variable domain immunoglobulin and uses thereof |
| CN105837690A (zh) * | 2006-06-12 | 2016-08-10 | 新兴产品开发西雅图有限公司 | 具有效应功能的单链多价结合蛋白 |
| EP2050764A1 (en) | 2007-10-15 | 2009-04-22 | sanofi-aventis | Novel polyvalent bispecific antibody format and uses thereof |
| CN102076355B (zh) * | 2008-04-29 | 2014-05-07 | Abbvie公司 | 双重可变结构域免疫球蛋白及其用途 |
| SG191639A1 (en) * | 2008-06-03 | 2013-07-31 | Abbott Lab | Dual variable domain immunoglobulins and uses thereof |
| AU2009268585C1 (en) * | 2008-07-08 | 2014-10-02 | Abbvie Inc. | Prostaglandin E2 dual variable domain immunoglobulins and uses thereof |
| US20110172398A1 (en) * | 2009-10-02 | 2011-07-14 | Boehringer Ingelheim International Gmbh | Bispecific binding molecules for anti-angiogenesis therapy |
| UY32979A (es) * | 2009-10-28 | 2011-02-28 | Abbott Lab | Inmunoglobulinas con dominio variable dual y usos de las mismas |
| EP2550297B1 (en) * | 2010-03-25 | 2019-01-23 | UCB Biopharma SPRL | Disulfide stabilized dvd-lg molecules |
| EP2571532B1 (en) * | 2010-05-14 | 2017-05-03 | Abbvie Inc. | Il-1 binding proteins |
| MX2013004979A (es) * | 2010-11-02 | 2013-07-30 | Abbott Lab | Inmunoglobulinas de dominio variable doble y usos de las mismas. |
| MY163368A (en) * | 2010-12-21 | 2017-09-15 | Abbvie Inc | Il-1-alpha and -beta bispecific dual variable domain immunoglobulins and their use |
-
2013
- 2013-11-01 BR BR112015009924A patent/BR112015009924A2/pt not_active Application Discontinuation
- 2013-11-01 CN CN201380057309.8A patent/CN105431453A/zh active Pending
- 2013-11-01 CA CA2889488A patent/CA2889488A1/en not_active Abandoned
- 2013-11-01 SG SG10201802044RA patent/SG10201802044RA/en unknown
- 2013-11-01 JP JP2015540830A patent/JP2016513069A/ja active Pending
- 2013-11-01 TW TW108137919A patent/TW202033215A/zh unknown
- 2013-11-01 EP EP18171273.8A patent/EP3466973A1/en not_active Withdrawn
- 2013-11-01 SG SG11201503324WA patent/SG11201503324WA/en unknown
- 2013-11-01 TW TW107111541A patent/TW201838651A/zh unknown
- 2013-11-01 TW TW102139863A patent/TW201422236A/zh unknown
- 2013-11-01 WO PCT/US2013/068110 patent/WO2014071212A2/en not_active Ceased
- 2013-11-01 RU RU2020139283A patent/RU2020139283A/ru unknown
- 2013-11-01 MX MX2015005495A patent/MX2015005495A/es unknown
- 2013-11-01 EP EP13792165.6A patent/EP2914626A2/en not_active Ceased
- 2013-11-01 RU RU2015120605A patent/RU2015120605A/ru unknown
- 2013-11-01 HK HK16101327.4A patent/HK1213204A1/zh unknown
- 2013-11-01 KR KR1020157013990A patent/KR20150079866A/ko not_active Abandoned
- 2013-11-01 AU AU2013337644A patent/AU2013337644A1/en not_active Abandoned
- 2013-11-01 US US14/070,155 patent/US20140161817A1/en not_active Abandoned
-
2015
- 2015-04-13 IL IL238264A patent/IL238264A0/en unknown
- 2015-04-29 MX MX2019003214A patent/MX2019003214A/es unknown
-
2016
- 2016-11-04 US US15/343,327 patent/US20170210796A1/en not_active Abandoned
-
2018
- 2018-10-24 AU AU2018253520A patent/AU2018253520A1/en not_active Abandoned
-
2019
- 2019-06-26 JP JP2019118152A patent/JP2019189633A/ja active Pending
-
2020
- 2020-01-17 US US16/745,579 patent/US20200385456A1/en not_active Abandoned
- 2020-08-12 IL IL276688A patent/IL276688A/en unknown
- 2020-09-30 AU AU2020244482A patent/AU2020244482A1/en not_active Abandoned
- 2020-10-26 JP JP2020178626A patent/JP2021020943A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2016513069A5 (enExample) | ||
| HRP20192202T1 (hr) | Acc inhibitori i njihove upotrebe | |
| JP2016512050A5 (enExample) | ||
| JP2012045397A5 (enExample) | ||
| EA201591004A1 (ru) | Производные бороновой кислоты и их терапевтическое применение | |
| CL2014003370A1 (es) | Composición acuosa estable de anticuerpos anti-baffr; y dispositivo de suministro de la composición. | |
| PL3060229T3 (pl) | Stabilne, wodne formulacje przeciwciała | |
| AR098168A1 (es) | Formulación estable de insulina glulisina | |
| TWD168530S (zh) | 容器 | |
| TWD167214S (zh) | 包裝用容器 | |
| TWD167749S (zh) | 電連接器 | |
| JP2016031825A5 (enExample) | ||
| JP2015516943A5 (enExample) | ||
| JP2013535391A5 (enExample) | ||
| JP2013227283A5 (enExample) | ||
| CY1123536T1 (el) | Τρυγικο αλας του 5-χλωρο-θειοφαινο-2-καρβοξυλικου οξεος [(s)-2-[meθyλo-3-(2-oξo-πυρρολιδιν-1-υλ)-βενζολοσουλφονυλαμινο]-3-(4-μεθυλο-πιπεραζιν-1-υλ)-3-οξο-προπυλ]αμιδιου | |
| JP2012186616A5 (enExample) | ||
| JP2016107746A5 (enExample) | ||
| JP2014159381A5 (enExample) | ||
| CN302028187S (zh) | 酒瓶（丰谷酒王15年） | |
| TWD162138S (zh) | 眼鏡（二） | |
| CN302314225S (zh) | 眼镜（tw14） | |
| CN302314221S (zh) | 眼镜（026） | |
| CN302314208S (zh) | 眼镜（tw13） | |
| TWD175622S (zh) | 可摺疊髮梳 |